Advertisement

Risikoanalyse der hormonalen Kontrazeption

  • B. Runnebaum
  • T. Rabe
Conference paper

Zusammenfassung

Im Hinblick auf die Anwendung kontrazeptiver Methoden ist es in der Zeit von 1970 bis 1980 zu deutlichen Veränderungen gekommen. Die hormonale Kontrazeption hat einen weiteren Aufschwung erfahren. Während noch 1970 etwa 30 Millionen Frauen die Pille zur Kontrazeption anwendeten, sind es zur Zeit 60–80 Millionen; insgesamt haben 150 Millionen Frauen bereits Erfahrung mit der hormonalen Kontrazeption. In den lateinamerikanischen Ländern sind mechanische Hilfen bei der Frau (Scheidendiaphragma) sowie Verhaltensmethoden mehr in den Vordergrund getreten. Das Intrauterinpessar konnte sich weltweit nur allmählich durchsetzen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Beral V, Ramcharan S, Fans R (1977): Malignant melanoma and oral contraceptive use among women in California. Brit J Cancer 36: 804–809PubMedCrossRefGoogle Scholar
  2. Eser A, Hirsch HA (Hrsg.) (1980): Sterilisation und Schwangerschaftsabbruch. Enke Verlag, StuttgartGoogle Scholar
  3. Jordan WM (1961): Pulmonary embolism. Lancet II 1146–1147CrossRefGoogle Scholar
  4. Grabowski MU, Stenram U, Bergqvist A (1975): Focal nodular hyperplasia of the liver, benign hepatomas, oral contraceptives and other drugs affecting the liver. Acta path microbiol scand Section A 83 615–622Google Scholar
  5. Hoover R, Bain C, Cole P, MacMahon B (1978): Oral contraceptive use: association with frequency of hospitalization and chronic disease risk indicators. Am J Public Health 68: 355–361CrossRefGoogle Scholar
  6. Mishell DR (1979): Oral Steroids, in: Reproductive Endocrinology, Infertility and Contraception, Davis Company, PhiladelphiaGoogle Scholar
  7. Morrison AS, Jick H, Ory HW (1977): Oral contraceptives and hepatitis. A report from the Boston Surveillance Program, Boston University Medical Center. Lancet I 1142–1143CrossRefGoogle Scholar
  8. Petitti DB, Wingerd J, Pelegrin F, Ramcharan S (1978): Oral contraceptives, smoking and other factors in relation to the risk of venous thromboembolic disease. Am J Epedem 108: 480–485Google Scholar
  9. Population Reports (1982): Oral Contraceptives: Oral contraceptives in the 1980s. Series A, Number 6, May-June. Population Information Program, The Johns Hopkins University, Baltimore, Maryland, USA.Google Scholar
  10. Rabe T, Runnebaum B (1982): Kontrazeption. Springer-Verlag, Berlin-Heidelberg-New YorkGoogle Scholar
  11. Ramcharan S, Pellegrin FA, Ray R, Hsu JP (1981): General description of the study; characteristics of the cohort; followup of the cohort. In: Ramcharan S, Pellegrin FA, Ray R and Hsu JP, The Walnut Creek Contraceptive Drug Study: a prospective study of the side effects of oral contraceptives. Vol. 3. An interim report - a comparison of disease occurence leading to hospitalization or death of users and nonusers of oral contraceptives. Bethesda, Maryland, Center for Population Research, p. 1–26Google Scholar
  12. Royal College of General Practitioners (1974): Oral contraception and health; an interim report from the oral contraception study of the Royal College of General Practitioners. Pitman New YorkGoogle Scholar
  13. Royal College of General Practitioners (1978): Oral Contraceptive Study: Oral Contraceptives, venous thrombosis and varicose veins. Journal of the Royal College of General Practitioners 28: 393–399Google Scholar
  14. Royal College of General Practitioners’ Oral Contraceptive Study (1977): Mortality among oral contraceptive users. Lancet II 727–731Google Scholar
  15. Royal College of General Practitioners Oral Contraceptive Study (1981): Further analyses of mortality in oral contraceptive users. Lancet 541–546Google Scholar
  16. Runnebaum B, Rabe T (1982): Risiko-Nutzen-Analyse der hormonalen Kontrazeption. Deutsches Ärzteblatt 79: 29–48Google Scholar
  17. Shapiro S, Slone D, Rosenberg L, Kaufman DW, Stolley PD, Miettinen OS (1979): Oral-contraceptive use in relation to myocardial infarction. Lancet I 743–747CrossRefGoogle Scholar
  18. Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD (1981): Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. New England J Med 305:420–424CrossRefGoogle Scholar
  19. Sturtevant FM (1979): Oral contraceptives and liver tumors, in: Controversies in Contraception. KS Moghissi (Hrsg.), The Williams & Wilkins Company, Baltimore 93–150Google Scholar
  20. Tietze CH, Lewit S (1977/1978): Mortality and Fertility Control. Int J Gynaecol Obstet 15: 100 and 16:456–459PubMedGoogle Scholar
  21. Vessey M, Doll R, Johnson B, Wiggins P (1976): A long-term follow-up study of women using different methods of contraception - an interim report. J Biosoc Sci 8: 375–427CrossRefGoogle Scholar
  22. Vessey MP, McPherson K, Johnson B (1977): Moratility among women participating in the Oxford/Family Planning Association contraceptive study. Lancet II 731–733CrossRefGoogle Scholar
  23. Vessey MP, Kay CR, Baldwin JA, Clarke B, MacLeod IB (1977): Oral contraceptives and benign liver tumours. Brit Med J II 1064CrossRefGoogle Scholar
  24. Wingrave SJ (1982): Progestogen effects and their relationship to lipoprotein Changes. Acta Obstet Gynecol Scand Suppl. 105: 33–36PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1985

Authors and Affiliations

  • B. Runnebaum
    • 1
  • T. Rabe
  1. 1.Abt. für Gynäkologische EndokrinologieUniversitäts-Frauenklinik HeidelbergHeidelbergGermany

Personalised recommendations